ProQR Therapeutics (PRQR) Beginning Cash Balance (2013 - 2026)

ProQR Therapeutics has reported Beginning Cash Balance for 13 years, with the latest figure at $140.0 million in Q3 2025.

• Quarterly Beginning Cash Balance rose 61.44% year-over-year to $140.0 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $476.2 million (up 6.25% YoY) and the FY2021 annual result came in at $89.7 million, down 29.79% from the prior year.
• Beginning Cash Balance retreated to $140.0 million in Q3 2025 per PRQR's latest filing, from $157.2 million in the prior quarter.
• Over five years, Beginning Cash Balance peaked at $210.5 million in Q1 2022 and troughed at $81.7 million in Q2 2021.
• A 5-year average of $137.4 million and a median of $140.0 million in 2025 frame the typical range for Beginning Cash Balance.
• The sharpest annual moves came in 2021 and 2023: Beginning Cash Balance surged 73920.16% in 2021, then tumbled 51.67% in 2023.
• Over 5 years, Beginning Cash Balance stood at $178.6 million in 2021, then fell by 11.71% to $157.7 million in 2022, then dropped by 11.25% to $140.0 million in 2023, then tumbled by 38.03% to $86.7 million in 2024, then soared by 61.44% to $140.0 million in 2025.
• According to Business Quant data, Beginning Cash Balance over the past three periods registered $140.0 million, $157.2 million, and $86.7 million for Q3 2025, Q1 2025, and Q3 2024 respectively.